Convatec
Convatec, a leading global medical products and technologies company, is proud to announce clinical study results from a recent multinational randomised controlled trial (RCT) showcasing remarkable advancements in the healing of venous leg ulcers with AQUACEL Ag+ Extra compared to standard of care dressing.
The multicentre RCT was conducted across 20 sites in Germany, United Kingdom and Colombia and investigated the effectiveness of AQUACEL Ag+ Extra compared to standard of care dressing in the management of patients with venous leg ulcers. The study found that venous leg ulcers managed with AQUACEL Ag+ Extra were 31% more likely to heal completely at 12 weeks and 31% more likely to have a 40% reduction in wound area at 4 weeks, compared to the standard of care dressing.
At 12 weeks, 74.8% of venous leg ulcers managed with AQUACEL Ag+ Extra had completely healed, compared to 55.6% of those managed with the standard of care dressing.
Venous ulcers currently affect a global population of over 143 million patients and pose a significant burden on healthcare systems worldwide, often requiring prolonged treatment and causing substantial morbidity. The findings from this RCT suggest that AQUACEL Ag+ Extra may provide an effective means of managing these hard-to-heal wounds.
AQUACEL Ag+ Extra dressings combine Hydrofiber Technology and MORE THAN SILVER Technology, a unique ionic silver-containing formulation. Hydrofiber technology works together with MORE THAN SILVER Ttechnology to absorb and remove wound exudate and disrupt and destroy biofilm components, helping to manage wound moisture and support healing.
“Chronic wound care management is a significant unmet patient need globally. These results represent our commitment to pioneering innovation and evidence-based solutions. We are excited and grateful to all our colleagues and external partners for driving this critical capability and improving outcomes for patients with venous leg ulcers," said Dr Divakar Ramakrishnan, Chief Technology Officer and Head of Research & Development at Convatec.
Dr Beate Hanson, Chief Medical Officer at Convatec, added: “We are pleased to announce these landmark study results, adding to the substantial existing evidence that AQUACEL Ag+ Extra is a unique and powerful antimicrobial and antibiofilm wound dressing. This study clearly demonstrates superiority of AQUACEL Ag+ Extra in the healing of venous leg ulcers when compared to standard of care. These new results highlight the clinical value of this best-in-class technology which may ultimately provide relief to these patients and improve their quality of life as part of our forever caring promise.
